The global migraine drugs market had a valuation of USD 6.7 Billion in 2022 and is anticipated to reach USD 10.9 Billion by 2032, exhibiting a robust compound annual growth rate (CAGR) of 4.7% throughout the forecast period. Key drivers of market revenue growth include the increasing prevalence of migraine worldwide, enhanced awareness among patients and physicians regarding the importance of...